ACT - AdvisorShares Vice ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
25.120
+0.010 (+0.04%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close25.110
Open25.080
Bid24.250 x 2200
Ask29.300 x 2200
Day's Range25.060 - 25.250
52 Week Range24.230 - 29.500
Volume8,897
Avg. Volume5,825
Net Assets12.57M
NAV25.15
PE Ratio (TTM)N/A
YieldN/A
YTD Return-3.85%
Beta (3y)0.00
Expense Ratio (net)0.00%
Inception Date2017-12-11
Trade prices are not sourced from all markets
  • 4/20: Marijuana, hemp legalization moves ahead in many states
    Yahoo Finance Videolast month

    4/20: Marijuana, hemp legalization moves ahead in many states

    Senate Democratic leader Chuck Schumer says he’s introducing a bill to decriminalize marijuana at the federal level. Yahoo Finance’s Alexis Christoforous and Dan Ahrens, Managing Director & COO at AdvisorShares, discuss marijuana and hemp sales.

  • Marijuana Stocks: This Unique Weed Merger Offers Tech, Eyes U.S. Listing
    Investor's Business Daily9 hours ago

    Marijuana Stocks: This Unique Weed Merger Offers Tech, Eyes U.S. Listing

    Cannabis tech and infrastructure outfit TILT Holdings is "absolutely" considering listing on a U.S. exchange after the company merges, its CEO told IBD in an interview.

  • Investopedia4 days ago

    Marijuana ETFs Experience Setbacks

    The legal marijuana industry is a nascent space that many investors believe is full of tremendous potential. It seems that almost every day there is news about a shift in legal status, a change in regulation and oversight, or some other adjustment. At the same time, though, marijuana exchange-traded funds (ETFs) have been in a holding pattern of sorts, according to etf.com.

  • 3 Marijuana ETFs for Everyday Investors to Play the Cannabis Movement
    InvestorPlace14 days ago

    3 Marijuana ETFs for Everyday Investors to Play the Cannabis Movement

    Four years ago, the marijuana legalization movement was firmly underway. Cannabis, both medical and recreational, was on more state ballots than ever before. And though many of those referendums were ultimately rejected, some got the green light. And simply appearing on a ballot at all was a victory for the cannabis industry.

  • Futures point slightly lower, Trump bashes OPEC over oil prices
    Yahoo Financelast month

    Futures point slightly lower, Trump bashes OPEC over oil prices

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.

  • American City Business Journals3 months ago

    United Therapeutics reaches patent settlement with Actavis

    Silver Spring biotech United Therapeutics Corp.'s share price was largely unchanged Friday after announcing it settled litigation with Actavis Laboratories FL Inc. in a deal that will allow that company to market a generic version of one of United Therapeutics' hypertension drugs. Under the settlement, United Therapeutics (UTHR) grants the Teva Pharmaceutical Industries Ltd. (TEVA) subsidiary a license to manufacture and commercialize a generic version of Orenitram — an extended-release, oral tablet form of treprostinil —beginning June 15, 2027. Actavis had filed a challenge seeking to market the generic Orenitram before United Therapeutics' patents expire between 2024 and 2031.

  • American City Business Journals3 months ago

    United Therapeutics settles patent litigation over $157M drug

    United Therapeutics has settled patent litigation over a $157 million drug. The company (UTHR) reached an agreement with Actavis Laboratories FL, which is a subsidiary of generic giant Teva Pharmaceuticals, that resolves litigation over certain patents related to one of United Therapeutics' pulmonary arterial hypertension drugs: Orenitram. The settlement agreement allows Actavis to begin manufacturing and commercializing a generic version of the drug in June 2027 or potentially earlier under some circumstances. However, United Therapeutics noted that the agreement doesn't allow Actavis to manufacture generic versions of other products like Tyvaso or Remodulin.

  • Marijuana and Blockchain: 2018's Hottest New ETFs
    Zacks3 months ago

    Marijuana and Blockchain: 2018's Hottest New ETFs

    You asked for them, and now they've arrived. ETFs for two of the top investing trends.

  • TheStreet.com3 months ago

    Allergan CEO: We Are Staying in Ireland

    On an earnings call, Allergan's top executive rejected the possibility of moving back to the U.S. on the heels of the new tax law.

  • Reuters4 months ago

    Allergan to pay Israel's Teva Pharm $700 million to settle dispute

    Allergan (AGN.N) will make a one-time payment of $700 million to Teva Pharmaceutical Industries (TEVA.TA) to settle a dispute over working capital, Israel-based Teva said on Thursday. Teva will use the payment, which is expected during the first quarter of 2018, to repay part of its debt. Teva (TEVA.N) and Allergan agreed to jointly dismiss the working capital dispute arbitration.

  • What Investors Need to Know About Marijuana ETFs
    Zacks4 months ago

    What Investors Need to Know About Marijuana ETFs

    Marijuana stocks and ETFs have been soaring despite regulatory uncertainty; here is what investors need to know.

  • Pot Stock Plays Fall, But Here's Why Jeff Sessions May Not Matter Much
    Investor's Business Daily5 months ago

    Pot Stock Plays Fall, But Here's Why Jeff Sessions May Not Matter Much

    Exchange traded funds tied to marijuana skidded on Thursday on a report that Attorney General Jeff Sessions planned to roll back the measure that encouraged more states in recent years to legalize usage of the plant. 

  • Forbes5 months ago

    Bill Ackman And Valeant Settle Allergan Insider Trading Lawsuit For $290 Million

    Hedge funder Bill Ackman and Valeant Pharmaceuticals will pay $290 million to settle claims from shareholders in Allergan they engaged in insider trading when pressing a takeover of the botox-maker in 2014. The settlement means Valeant likely cost Pershing $4 billion.

  • Reuters5 months ago

    Pershing Square, Valeant arrive at settlement split for Allergan lawsuit

    Pershing Square said it decided to raise its share of the settlement to 66.8 percent, or $193.75 million, in a bid to quickly wind up the litigation, which it claimed had "no merit". "We decided, however, that it was in the best interest of our investors to settle the case now instead of continuing to spend substantial time and resources pursuing the litigation," said Pershing Square CEO Bill Ackman. The hedge fund said Valeant will now pay around 33 percent, or $96.25 million, of the settlement costs.

  • Rush for Marijuana ETFs Getting Stronger
    Zacks5 months ago

    Rush for Marijuana ETFs Getting Stronger

    Teucrium plans for an Emerging Medical Agriculture Index Fund. Does this hint at a marijuana ETF?

  • ETF Database5 months ago

    This Week's ETF Launches: Introducing the First Quadruple-Leveraged Products

    Triple-leveraged ETFs – funds that mainly use futures to ratchet up the exposure to a specific asset – have long been considered one of Wall Street’s riskiest products. This week, those funds take a back seat to the newly launched quadruple-leveraged exchange-traded notes brought to the market by Citigroup.

  • ETF Trends5 months ago

    Sin Is In With New Vice ETF

    AdvisorShares, an exchange traded fund provider known for its actively managed investment options, has launched a new ETF that capitalizes on vice and also one among the first to include targeted exposure ...

  • PR Newswire5 months ago

    AdvisorShares Delivers Alcohol, Cannabis & Tobacco Exposure with New Actively Managed ETF

    BETHESDA, Md., Dec. 11, 2017 /PRNewswire/ -- AdvisorShares, a leading sponsor of actively managed exchange-traded funds (ETFs), announced today that the AdvisorShares Vice ETF (Ticker: ACT) will begin trading on Tuesday, December 12, 2017. ACT becomes the first ETF – among both passively managed and actively managed strategies – that provides concentrated exposure to select companies associated with alcohol, cannabis and tobacco. ACT's portfolio management team carries extensive experience in the capital markets and a well-established expertise of investing in this area of the equity markets, which includes the founder and original portfolio manager of the Vice Fund mutual fund (VICEX).

  • Reuters9 months ago

    Drugmaker Teva looks to sell Medis business to help cut debt

    Teva Pharmaceutical Industries , the world's largest generic drugmaker, said on Wednesday it was looking for a buyer for its Medis business as it sells assets to pare down its debt burden. Teva, which last week reported a drop in second-quarter results and cut its outlook and dividend, acquired Iceland-based Medis as part of its acquisition of Actavis last year. "Teva is looking at every opportunity to focus our business and streamline operations, processes and structure," Teva said in an emailed statement to Reuters.